Deals report: Ipsen gets second ADC; Context buys MSLNxCD3 bispecific

The past seven days brought at least eight new partnerships, including a deal for up to $1 billion between Ipsen and Foreseen, two asset purchases and the acquisitions of Meilleur and Fluent. 

Following up an April deal that gave it access to its first antibody-drug conjugate, ROR1-targeting STRO-003 from Sutro Biopharma Inc. (NASDAQ:STRO),  Ipsen Group (Euronext:IPN; Pink:IPSEY) has licensed FS001, an ADC from Foreseen Biotechnology. FS001 targets an undisclosed tumor antigen and employs a cleavable linker coupled to a TOP1 inhibitor. Foreseen is eligible for up to $1 billion in upfront and milestone payments. Ipsen will carry out IND submission and Phase I studies for FS001, which showed preclinical efficacy in multi-drug resistant cancer models. ...